4-Methylmorpholine → 3-tert-Butyl-N-(3-{6-[1-(4-methoxybenzyl)-1H-pyrazol-4-yl]-1H-imidazo[1,2-b]pyrazol-1-yl}-4-methylphenyl)-5-(4-methylpiperazin-1-yl)benzamide

HRID 1055674ノート

反応式

HRID 1055674 の反応式
F[C:2](F)(F)[C:3]([OH:5])=O.COC1C=CC([CH2:14][N:15]2[CH:19]=[C:18]([C:20]3[CH:21]=[C:22]4[N:27]([C:28]5[CH:29]=[C:30]([CH:32]=[CH:33][C:34]=5[CH3:35])[NH2:31])[CH:26]=[CH:25][N:23]4[N:24]=3)[CH:17]=[N:16]2)=CC=1.F[C:39](F)(F)C(O)=O.[C:45]([C:49]1[CH:50]=[C:51]([CH:55]=[C:56]([N:58]2[CH2:63][CH2:62][N:61]([CH3:64])[CH2:60][CH2:59]2)[CH:57]=1)[C:52](O)=[O:53])([CH3:48])([CH3:47])[CH3:46].CN(C(ON1N=N[C:75]2[CH:76]=[CH:77]C=N[C:74]1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CN1CCOCC1.[OH-].[Na+]>CN(C=O)C>[C:45]([C:49]1[CH:50]=[C:51]([CH:55]=[C:56]([N:58]2[CH2:63][CH2:62][N:61]([CH3:64])[CH2:60][CH2:59]2)[CH:57]=1)[C:52]([NH:31][C:30]1[CH:32]=[CH:33][C:34]([CH3:35])=[C:28]([N:27]2[C:22]3[N:23]([N:24]=[C:20]([C:18]4[CH:17]=[N:16][N:15]([CH2:14][C:75]5[CH:74]=[CH:2][C:3]([O:5][CH3:39])=[CH:77][CH:76]=5)[CH:19]=4)[CH:21]=3)[CH:25]=[CH:26]2)[CH:29]=1)=[O:53])([CH3:48])([CH3:47])[CH3:46]

参加物

7

実験手順

65 mg (0.13 mmol) of the compound of Example 8A, 50 mg (0.13 mmol) of the compound of Example 21A and 58 mg (0.15 mmol) of HATU were dissolved in 0.73 ml of DMF, 0.07 ml (0.63 mmol) of 4-methylmorpholine was added and the mixture was stirred at RT for 16 h. 10 ml of 0.1 M aqueous sodium hydroxide solution were then added, and the mixture was stirred at RT for another 10 min. The precipitate formed was filtered off, washed with water and dried under high vacuum. This gave 70 mg (76% pure, 64% of theory) of the title compound.

後処理

  1. stirringthe mixture was stirred at RT for another 10 min
  2. customThe precipitate formed
  3. filtrationwas filtered off
  4. washwashed with water
  5. customdried under high vacuum

出典と根拠

ORDレコード
ord-ce50c68d8223493abb2f064faca2495d
出典データセット
uspto-grants-2016_07
特許番号
US09394309B2

反応ノート

読み込み中…